Augmentation of Murine Natural Killer Cell Activity by Swainsonine, a New Antimetastatic Immunomodulator

Cancer Research

Volumn 48, Issue 6, 1988, Pages 1410-1415

  Humphries, Martin J ^a   Matsumoto, Kazue ^a   White, Sandra ^b   Molyneux, Russell J ^b   Olden, Kenneth ^b  

^a HOWARD UNIVERSITY CANCER CENTER   (United States)

^b WESTERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; IMMUNOMODULATING AGENT; SWAINSONINE;

ANIMAL EXPERIMENT; LUNG METASTASIS; MELANOMA B16; NATURAL KILLER CELL; NONHUMAN;

ADJUVANTS, IMMUNOLOGIC; ALKALOIDS; ANIMAL; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; GLYCOSPHINGOLIPIDS; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SWAINSONINE; TIME FACTORS;

EID: 0023877318     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Terry, W. D., and Rosenberg, S. A. (eds.). Immunotherapy of Human Cancer. New York Elsevier North-Holland, 1982.
2. Herberman, R. B. Biological response modifiers for the therapy of cancer. In: E. Tsubura, I. Urushizaki, T. Aoki, S. Sone, and Y. Kaneko (eds.), Rationale of Biological Response Modifiers in Cancer Treatment, pp. 240–255. Princeton: Excerpta Medica, 1985.
3. Rosenberg, S. A., and Lotze, M. T. Cancer immunotherapy using interleulcin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol., 4: 681-709,1986.
4. Forni, G., Giovarelli, M., Santoni, A., Modesti, A., and Forni, M. Tumour inhibition by interleukin-2 at the tumour/host interface. Biochim. Biophys. Acta, 865:307-327, 1986.
5. Talmadge, J. E., and Herberman, R. B. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep., 70:171-182, 1986.
6. Hollinshead, A. Immunotherapy trials: current status and future directions with special emphasis on biologic drugs. Springer Semin. Immunopathol., 9: 85–103, 1986.
7. Lotze, M. T., Frana, L. W., Sharrow, S. O., Robb, R. J., and Rosenberg, S. A. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol., 134:157-166,1985.
8. Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Raynor, A. A., Sharrow, S. O., Seipp, C. A., Custer, M. C., and Rosenberg, S. A. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol., 135:2865-2875,1985.